KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Globus Medical (GMED) Shares Outstanding (Diluted Average) (2016 - 2025)

Globus Medical's Shares Outstanding (Diluted Average) history spans 13 years, with the latest figure at $137.1 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) fell 0.59% year-over-year to $137.1 million; the TTM value through Dec 2025 reached $137.1 million, down 0.59%, while the annual FY2025 figure was $137.1 million, 0.59% down from the prior year.
  • Shares Outstanding (Diluted Average) reached $137.1 million in Q4 2025 per GMED's latest filing, down from $137.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $137.9 million in Q4 2024 to a low of $114.6 million in Q4 2023.
  • Average Shares Outstanding (Diluted Average) over 3 years is $129.8 million, with a median of $137.1 million recorded in 2025.
  • Peak YoY movement for Shares Outstanding (Diluted Average): rose 20.27% in 2024, then decreased 0.59% in 2025.
  • A 3-year view of Shares Outstanding (Diluted Average) shows it stood at $114.6 million in 2023, then rose by 20.27% to $137.9 million in 2024, then dropped by 0.59% to $137.1 million in 2025.
  • Per Business Quant, the three most recent readings for GMED's Shares Outstanding (Diluted Average) are $137.1 million (Q4 2025), $137.9 million (Q4 2024), and $114.6 million (Q4 2023).